51. Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer.
- Author
-
Yoshida Y, Naito M, Yamada T, Aisu N, Daibo K, Mera T, Tanaka T, Naito K, Yasumoto K, Kamigaki T, Goto S, Yamashita Y, and Hasegawa S
- Subjects
- Adenocarcinoma mortality, Adenocarcinoma secondary, Aged, Aged, 80 and over, Bevacizumab administration & dosage, Capecitabine, Colorectal Neoplasms mortality, Colorectal Neoplasms pathology, Combined Modality Therapy, Deoxycytidine therapeutic use, Disease-Free Survival, Female, Fluorouracil therapeutic use, Humans, Immunotherapy, Adoptive, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Staging, Oxaloacetates, Retrospective Studies, T-Lymphocyte Subsets immunology, T-Lymphocyte Subsets transplantation, Treatment Outcome, Adenocarcinoma therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms therapy, Deoxycytidine analogs & derivatives, Fluorouracil analogs & derivatives
- Abstract
Background/aim: Adoptive immunotherapy of cancer is evolving with the development of novel technologies that generate proliferation of large numbers of αβ and γδ T cells. We evaluated the safety and efficacy of the combination of adoptive immunotherapy using αβ T cells with chemotherapy for stage IV colorectal cancer (CRC)., Patients and Methods: Fifteen patients with advanced or recurrent CRC received XELOX + bevacizumab + ex vivo expanded αβ T lymphocytes as a first-line chemoimmunotherapy., Results: Median age of the 15 patients (4 men, 11 women) was 65 years (range=49-80). Median progression-free survival was 21.3 months. Response rate was 80% (complete response (CR)=26.7%, partial response (PR)=53.3%, stable disease (SD)=20% and progressive disease (PD)=0%). Most adverse events were mild to moderate regarding their intensity and immunotherapy-associated toxicity was minimal., Conclusion: Combination of adoptive αβ T cell immunotherapy with chemotherapy for stage IV CRC is feasible and safe., (Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)
- Published
- 2016